+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Drugs for Parkinson's Disease Market - Global Forecast 2025-2030- Product Image
Targeted Drugs for Parkinson's Disease Market - Global Forecast 2025-2030- Product Image
Sale

Targeted Drugs for Parkinson's Disease Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080541
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The targeted Parkinson’s disease therapeutics market is entering a pivotal era, driven by scientific advances and the growing complexity of patient needs. As the focus shifts toward precision treatments, senior healthcare leaders face a dynamic environment shaped by innovation, regulatory change, and strategic competition.

Market Snapshot: Precision Parkinson’s Disease Therapeutics

The Parkinson’s disease therapeutics market is poised for substantial expansion, with notable advances in disease-modifying treatments and emerging modalities such as gene therapies and novel biologics. A rising prevalence, driven by an aging global population, fuels increasing demand for interventions that address both motor and nonmotor symptoms. The landscape features heightened activity across R&D, regulatory adaptation, and collaborative frameworks, signaling strong growth prospects and a rapidly evolving ecosystem.

Scope & Segmentation: In-Depth Analysis

This report provides strategic coverage of the Parkinson’s disease therapeutics ecosystem, offering deep-dive segmentation to inform market positioning and decision-making:

  • Therapy Type: Anticholinergics, Carbidopa Levodopa, COMT Inhibitors, Dopamine Agonists, MAO-B Inhibitors
  • Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Route of Administration: Injectable, Oral, Transdermal
  • Disease Stage: Advanced Stage, Early Stage
  • End User: Clinics, Homecare, Hospitals, Specialty Clinics
  • Patient Age Group: Adult, Geriatric
  • Price Range: Economy, Mid Range, Premium
  • Regional Coverage: Americas (with United States sub-state detail, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including EMEA countries), Asia-Pacific (including major and emerging countries)
  • Company Coverage: Key profiled organizations include AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Novartis AG, Lundbeck A/S, Boehringer Ingelheim International GmbH, Acorda Therapeutics, Inc., UCB S.A., Sun Pharmaceutical Industries Limited, Viatris Inc.

Key Takeaways for Senior Decision-Makers

  • Emerging gene and cell therapies are reshaping the clinical approach to Parkinson’s disease, moving beyond symptom management to potential disease modification.
  • Strategic alliances between pharmaceutical leaders, biotechs, and academic institutions accelerate preclinical progress and facilitate commercialization of advanced modalities.
  • Digital biomarkers and machine learning are improving patient stratification, trial execution, and real-world monitoring, enhancing evidence generation and paving the way for value-based care models.
  • Market access increasingly depends on the ability to align clinical development with health economics, payer requirements, and differentiated product positioning informed by robust patient and product segmentation.
  • Supply chain resilience and nearshoring strategies are becoming essential due to changing tariff regimes and global trade dynamics, prompting investment shifts in manufacturing footprints.
  • Regulatory evolution, including adaptive trial designs and conditional approvals, is enabling quicker entry for innovative therapies while maintaining high safety standards.

Tariff Impact: Navigating 2025 U.S. Policy Changes

The 2025 imposition of new U.S. tariffs on pharmaceutical ingredients is reshaping cost structures for Parkinson’s disease drug manufacturers. Companies are altering sourcing strategies, diversifying suppliers, and increasing domestic production to manage growing raw material and logistical expenses. These tariffs necessitate agile financial planning, more stringent trial budgeting, and enhanced enterprise risk management to maintain uninterrupted therapy supply chains amid volatility.

Methodology & Data Sources

Research integrates secondary data review with in-depth interviews of key stakeholders, including clinicians, industry executives, and supply chain specialists. Data triangulation and scenario modeling ensure accuracy, while internal peer review validates findings across all segments and geographies.

Why This Report Matters: Actionable Insights for Strategy

  • Enables informed decisions by mapping trends across therapies, technologies, and channels relevant to Parkinson’s disease treatment innovation.
  • Equips leaders to anticipate the implications of regulatory changes, market access shifts, and tariff impacts on operations and investment planning.
  • Supports targeted business development by profiling key competitors, identifying partnership opportunities, and highlighting emerging regions.

Conclusion

With multi-layered analysis across product, distribution, and regional segments, this report empowers senior executives to navigate the opportunities and challenges in the Parkinson’s disease therapeutics market. Strategic focus on precision interventions, resilient supply chains, and real-world evidence integration will help organizations achieve performance objectives and deliver improved patient outcomes.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancement in LRRK2 inhibitors targeting genetic mutations for precision therapy in Parkinson's disease
5.2. Development of alpha-synuclein monoclonal antibodies for disease modification in Parkinson's disease
5.3. Emergence of gene therapy approaches using viral vectors to restore dopaminergic function in Parkinson's disease
5.4. Integration of biomarkers and PET imaging to stratify patients and monitor disease progression in Parkinson's disease
5.5. Progress in small molecule retinoic acid receptor agonists to enhance neuroprotection in Parkinson's disease
5.6. Exploration of gut microbiome modulation to influence neuroinflammation and disease progression in Parkinson's disease
5.7. Combination therapies leveraging adenosine A2A antagonists and MAO-B inhibitors for symptomatic relief and neuroprotection in Parkinson's disease
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Drugs for Parkinson's Disease Market, by Therapy Type
8.1. Introduction
8.2. Anticholinergics
8.3. Carbidopa Levodopa
8.4. Comt Inhibitors
8.5. Dopamine Agonists
8.6. Mao-B Inhibitors
9. Targeted Drugs for Parkinson's Disease Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Targeted Drugs for Parkinson's Disease Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Transdermal
11. Targeted Drugs for Parkinson's Disease Market, by Disease Stage
11.1. Introduction
11.2. Advanced Stage
11.3. Early Stage
12. Targeted Drugs for Parkinson's Disease Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
12.5. Specialty Clinics
13. Targeted Drugs for Parkinson's Disease Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
14. Targeted Drugs for Parkinson's Disease Market, by Price Range
14.1. Introduction
14.2. Economy
14.3. Mid Range
14.4. Premium
15. Americas Targeted Drugs for Parkinson's Disease Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Targeted Drugs for Parkinson's Disease Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Targeted Drugs for Parkinson's Disease Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AbbVie Inc.
18.3.2. Teva Pharmaceutical Industries Ltd.
18.3.3. Merck & Co., Inc.
18.3.4. Novartis AG
18.3.5. Lundbeck A/S
18.3.6. Boehringer Ingelheim International GmbH
18.3.7. Acorda Therapeutics, Inc.
18.3.8. UCB S.A.
18.3.9. Sun Pharmaceutical Industries Limited
18.3.10. Viatris Inc.
19. Research AI20. Research Statistics21. Research Contacts22. Research Articles23. Appendix
List of Figures
FIGURE 1. TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET: RESEARCHAI
FIGURE 30. TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET: RESEARCHSTATISTICS
FIGURE 31. TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET: RESEARCHCONTACTS
FIGURE 32. TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY CARBIDOPA LEVODOPA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY CARBIDOPA LEVODOPA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ECONOMY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ECONOMY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY MID RANGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY MID RANGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PREMIUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PREMIUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 100. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 101. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 106. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 107. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 112. CANADA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 113. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 114. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 124. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 125. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 185. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 186. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 187. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 192. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 193. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 196. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 197. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 198. GERMANY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 199. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 200. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 201. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 206. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 207. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 212. FRANCE TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 227. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 228. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 229. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 234. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 235. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 238. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 239. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 240. ITALY TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 241. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 242. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 243. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 248. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 249. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 252. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 253. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 254. SPAIN TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PRICE RANGE, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA TARGETED DRUGS FOR PARKINSON'S DISEASE MARKET SIZ

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Targeted Drugs for Parkinson's Disease market report include:
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Lundbeck A/S
  • Boehringer Ingelheim International GmbH
  • Acorda Therapeutics, Inc.
  • UCB S.A.
  • Sun Pharmaceutical Industries Limited
  • Viatris Inc.

Related Topics

Related Reports

Anti-Parkinson's Disease Drugs Market - Global Forecast 2025-2030 - Product Image

Anti-Parkinson's Disease Drugs Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Parkinson's Disease Market Report and Forecast 2025-2034 - Product Image

Parkinson's Disease Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Parkinson's Disease Therapeutics Market - Global Forecast 2025-2030 - Product Image

Parkinson's Disease Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Parkinsons Disease Market - Product Image

Parkinsons Disease Market

  • Report
  • 250 Pages
  • Global
From
Parkinson's Disease Drugs - Global Strategic Business Report - Product Image

Parkinson's Disease Drugs - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.